normative

Marginal improvements get patent-protected and over-prescribed

Small incremental improvements—such as a drug absorbed more easily or taken less often—are awarded patent monopolies and priced many-fold above generics, then preferentially prescribed even though the system fails to encourage patients toward equally effective generics, which is a serious flaw of the current arrangement.

normativepending

Speaker

Russ Roberts

Evidence Quote

“it seems to me that should not be privileged with the monopoly of a patent”

Source

Adam Cifu on the Case for Being a Medical Conservative— EconTalk
Created: 6/13/2026, 12:18:13 AM

Your notes

Loading notes...